The National Institute for Health and Care Excellence
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Roche and Nurix Therapeutics to partner in $2.3bn deal
The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
Allergan Aesthetics launches Skin Quality Index for aesthetic consultations
Spanning four dimensions of skin health, the framework introduces 15 terms and definitions
One-carbon Therapeutics collaborates with Tempus in cancer treatment
The treatment is currently being evaluated in a phase 1/2 multicentre clinical study
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline
The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m
AbbVie reaches agreement for affordable prescription drugs with US government
The pharma company has also pledged a $100bn investment in US infrastructure over the next decade